Search
Search Results
-
Immunotherapy in Breast Cancer
Breast cancer affects 12% of women worldwide. Although advances in systemic, surgical, and radiation therapy approaches will cure a large proportion...
-
Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy
This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast...
-
Breast Cancer
Breast cancer is currently the most diagnosed cancer in the female population, with a prevalence of 1 in 8 women.
-
Biosimilars in Breast Cancer
Breast cancer is a significant health concern globally, leading to maximum mortalities amongst women worldwide, which is 11.6% of all cancers...
-
CTCs in Early Breast Cancer
In the last decades, treatment options for breast cancer patients improved rapidly, leading to a more personalized treatment approach. At the moment,...
-
Resistance to Targeted Therapy in Breast Cancer
The discoveries of breast cancer molecular subtypes and their deregulated pathways have given rise to the emergence of potential therapeutic targets...
-
Mechanisms of Drug Resistance in Breast Cancer
The incidence of breast cancer has increased over the past decades making it the most common cancer in females worldwide. Multidrug resistance (MDR)...
-
Resistance to Immunotherapy in Breast Cancer
Breast cancer is the most common and second most deadly disease in women worldwide, with breast cancer screening resulting in a steady decline in...
-
Introduction to Breast Cancer
Breast cancer is the leading cause of mortality among women worldwide. Being a heterogenous disease it comprises many different subtypes that differ...
-
CDK Dysregulation in Breast Cancer: A Bioinformatics Analysis
Breast cancer is one of the most common types of malignancy diagnosed among females worldwide. Due to its heterogenous nature, the type of treatment...
-
Gene signatures in patients with early breast cancer and relapse despite pathologic complete response
A substantial minority of early breast cancer (EBC) patients relapse despite their tumors achieving pathologic complete response (pCR) after...
-
MiR-662 is associated with metastatic relapse in early-stage breast cancer and promotes metastasis by stimulating cancer cell stemness
BackgroundBreast cancer (BC) metastasis, which often occurs in bone, contributes substantially to mortality. MicroRNAs play a fundamental role in BC...
-
Molecular Pathways in Breast Cancer Chemoresistance
Chemoresistance is one of the determinants of breast cancer (BrCA) prognosis. Chemoresistance leads to recurrence and metastasis that causes adverse...
-
Advancing Beyond Breast Cancer Resistance: A Glimmer of Hope
This comprehensive exploration delves into the intricate landscape of breast cancer treatment resistance, offering insights into mechanisms and...
-
Breast Cancer Therapy and Control
We discuss breast cancer therapy using drugs in this chapter. Genetic mutations are usually irreversible and they cannot be altered by giving drugs...
-
Current Treatment Approaches to Breast Cancer
Breast cancer is a familiar malignancy and the major reason for cancer mortality among females worldwide. Research on breast carcinoma has led to...
-
Emerging Therapeutic Approaches in Drug-Resistant Breast Cancer
Breast cancer, a heterogeneous and complex disease, remains a significant healthcare challenge around the world, with drug resistance being a major...
-
Breast Cancer: Epidemiology, Types, Diagnosis, and Treatment
Breast cancer is a complex disease, and many aspects of this disease are under intensive research. Better treatment of breast cancer can only be...
-
Cell Cycle Dysregulation in Breast Cancer
Cancer, a condition characterized by abnormal cell growth, is closely linked to the cell cycle. In reaction to mitogenic cues, all malignancies...
-
Identification of a novel ER-NFĸB-driven stem-like cell population associated with relapse of ER+ breast tumors
BackgroundUp to 40% of patients with estrogen receptor-positive (ER+) breast cancer experience relapse. This can be attributed to breast cancer stem...
